MedTrace Logo

LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy

NCT01986777 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-09-18

No results posted yet for this study

Summary

This is a double-blind, placebo-controlled, study testing whether LDX improves cognitive function and EF in 20 postmenopausal women who report onset of cognitive difficulties after oophorectomy (with or without subsequent chemo/adjunctive therapy). Brain imaging is included at critical time points to obtain objective data regarding effects of LDX as well as potential predictors of resilience in the face of oophorectomy.

Conditions

  • Cognitive Impairments
  • RRSO

Interventions

DRUG

lisdexamfetamine

DRUG

Placebo

The placebo capsules will be filled with lactose.

Sponsors & Collaborators

Principal Investigators

  • C. Neill Epperson, MD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01986777 on ClinicalTrials.gov